Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Home
Profiles
Research units
Research output
Search by expertise, name or affiliation
‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab
The REGAIN Study Group
School of Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
3
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of '‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Symptom
100%
Myasthenia gravis
100%
Eculizumab
100%
Cholinergic Receptor Antibody
100%
Activity of Daily Living Scale
45%
Placebo
27%
Patient-Reported Outcome
18%
Quality of Life
9%
Placebo-Controlled Study
9%
Mental Capacity
9%
Pharmacology, Toxicology and Pharmaceutical Science
Symptom
100%
Eculizumab
100%
Myasthenia gravis
100%
Cholinergic Receptor Antibody
100%
Placebo
27%
Tolerability
18%
Placebo-Controlled Study
9%
Neuroscience
Cholinergic Receptor Antibody
100%
Myasthenia gravis
100%
Eculizumab
100%
Placebo
36%
Keyphrases
Minimal Symptom Expression
100%
MG-QOL15
45%